Results 181 to 190 of about 75,890 (310)

Advances in locally advanced pancreatic cancer treatment

, 2017
Pancreatic cancer is the fourth leading cause of cancer related death in the Western world. The survival of patients with pancreatic cancer has not improved substantially over nearly 40 years with a current overall 5-years survival of only 7%. Surgical resection provides the best chance of survival.
openaire   +1 more source

Iron Physiology and Its Impact on Atopic Diseases: An EAACI Taskforce Report

Allergy, EarlyView.
ABSTRACT Iron is essential for oxygen transport, energy metabolism, and immune regulation. Yet iron deficiency is the most common micronutrient disorder across all age groups, affecting nearly one quarter of the global population. Iron deficiency triggers nutritional immunity, a host defense mechanism that withholds and redistributes iron, contributing
Franziska Roth‐Walter, Ioana Agache, Beatriz Cabanillas, Roberto Berni Canani, Pasquale Comberiati, Holger Garn, Cristina Gomez‐Casado, Karin Hufnagl, Ekaterina Khaleva, Gregorio P. Milani, Daniel Munblit, Nikolaos Douladiris, Liam O'Mahony, Frank Redegeld, Carmen Riggioni, Peter K. Smith, Betty van Esch, Emilia Vassilopoulou, Carina Venter, Diego G. Peroni   +19 more
wiley   +1 more source

The role of chemoradiotherapy after induction in locally advanced pancreatic cancer: lessons learnt from CONKO-007. [PDF]

J Gastrointest Oncol
Athanasiou C, Pandanaboyana S.
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN. [PDF]

J Clin Oncol
Nichetti F, Procaccio L, Lonardi S, Bergamo F.   +3 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer. [PDF]

Korean J Radiol
Kwon JH, Kim MD, Alanazi MS, Suk J, Jeong S, Bang S, Chung MJ, Hwang HK, Hong SS, Han K, Kim GM, Won JY, Park J, Cho J, Jeong SM, Choi TY.   +15 more
europepmc   +1 more source

Degradomics for large‐scale mechanistic insights on proteases and proteolysis in human health

The FEBS Journal, EarlyView.
Proteolysis has an important role in human disease but remains relatively unexplored. Degradomics, the uncovering of proteolysis in tissues, cells, and proteins, uses mass spectrometry‐based terminomics to identify protein termini occurring therein (forward degradomics) and to define the actions of proteases (reverse degradomics).
Daniel R. Martin, Sumit Bhutada, Suneel S. Apte   +2 more
wiley   +1 more source

AK112 (PD-1/VEGF-a bispecific antibody) combined with chemotherapy in locally advanced pancreatic cancer: a case report. [PDF]

Front Oncol
Yan J, Dong H, Wu C, Gu H, Qi Z, Chen T, Hu B, Zhou H, Long J.   +8 more
europepmc   +1 more source

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source